Enrollment in all ongoing Depatux-M studies has been halted for newly diagnosed glioblastoma due to lack of survival benefit.
We had the pleasure of speaking with Manmeet Ahluwalia about current vaccine options for glioblastoma, including a survivin vaccine (SurVaxM) for newly diagnosed glioblastoma.
Researchers have discovered administering pembrolizumab before surgery is more effective for the treatment of recurrent glioblastoma, than when administering the drug afterwards.
In this interview, we spoke with Justin Lathia about sexual dimorphism in glioblastoma, including his talk on sex differences in microglia and the glioma microenvironment.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A valuable cache of brain cancer biomedical data, termed REMBRANDT, has been made freely accessible to researchers worldwide.
Interim results from a Phase III trial of DCVax®-L have revealed that the vaccine could be safe in glioblastoma patients and may extend survival.
From novel biomarkers, to the potential use of the Zika virus as a tumor treatment, read our round-up of the biggest neuro-oncology news from the last year as we mark World Cancer Day.
Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard
Discover how combined-modality hypofractionated radiotherapy could become the new standard of care for elderly patients with glioblastoma in this editorial from Future Science OA.
Researchers have demonstrated that the enzymatic activity of R5 receptor-type protein tyrosine phosphatases is a requisite for the maintenance of stem cell properties and tumorigenicity in glioblastoma cells and could be a promising drug target for treatment.